Literature DB >> 34376794

Retraction Note: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy.

V La1, R Fujikawa1, D M Janzen1, M Nunez1, L Bainvoll1, L Hwang2,3,4, K Faull2,3,4, G Lawson5, S Memarzadeh6,7,8,9,10.   

Abstract

Entities:  

Year:  2021        PMID: 34376794      PMCID: PMC8355127          DOI: 10.1038/s41698-021-00217-9

Source DB:  PubMed          Journal:  NPJ Precis Oncol        ISSN: 2397-768X


× No keyword cloud information.
Retraction of: npj Precision Oncology 10.1038/s41698-017-0008-z, published online 03 April 2017 This Article[1] has been retracted by the Authors because concerns have been raised regarding the identity of the cell lines used for the experimental work. Specifically, re-analysis showed that the S1GODL xenografts matched STR profiles of Ovcar-3 cells, and review of raw flow cytometry data was found to be discordant with presented data. In light of these findings, the identity of the cells within the experimental groups in the manuscript is uncertain, and the conclusions of the work are not reliable. Authors Vincent La, Rachel Fujikawa, Deanna Janzen, Miguel Nunez, Lin Hwang, Kym Faull, Greg Lawson, and Sanaz Memarzadeh agree with this attraction. Liat Bainvoll did not respond to correspondence from the Publisher about this retraction.
  1 in total

1.  Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy.

Authors:  V La; R Fujikawa; D M Janzen; M Nunez; L Bainvoll; L Hwang; K Faull; G Lawson; S Memarzadeh
Journal:  NPJ Precis Oncol       Date:  2017-04-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.